OptiScanner Versus Standard Blood Glucose Monitoring
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study is to demonstrate the accuracy of the OptiScanner in measuring blood glucose levels in critically ill patients when compared to a reference YSI 2300 STAT Plus and the Gem 3000, the reference standard for Erasme University Hospital.
| Condition |
|---|
|
Hyperglycemia |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Manual vs. Automated moNitoring Accuracy of GlucosE II (MANAGE II) |
- Glucose Prediction error [ Time Frame: 1 year ] [ Designated as safety issue: No ]Percent (%) predicted error is the percent (%) error result of the OptiScanner on central venous blood from the superior cava versus the YSI and the GEM using arterial blood.
- Clarke Error Grid analysis [ Time Frame: 1 year ] [ Designated as safety issue: No ]The Clarke Error Grid analysis shows the percentage of paired values falling within each zone between the glucose results of the OptiScanner on central venous versus the YSI and the GEM using arterial blood.
Biospecimen Retention: Samples Without DNA
One additional blood sample (4 ml)will be collected once a day, separated into Draw an additional ~ 4.0 mL from the subject into a syringe once per every 24 hour period. The study site will indicate where and at what time the sample was taken. This sample is placed into a sodium heparin tube, labeled with the subject number and sampling time and centrifuged on a refrigerated centrifuge. The gained plasma will be frozen at minus 70 degrees Celsius or less and may be used for potential analysis by the Sponsor, should an analysis of outliers indicate the potential presence of an interferent.
| Estimated Enrollment: | 55 |
| Study Start Date: | July 2012 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Critically ill patients admitted to the intensive care unit (ICU) of Erasme University Hospital in Brussels, Belgium.
Inclusion Criteria:
- Signed Informed consent.
- Age ≥ 18 years.
- Admitted to the ICU of Erasme University Hospital.
- Expected ICU stay of ≥ 3 days at the time of enrollment (as judged by the Principle Investigator).
- APACHE II score of ≥ 10, within the first 24 hours of ICU admission.
- Existing central venous catheter + arterial catheter.
- No participation in any other investigational interventional study while enrolled in this study.
- Hyperglycemia (BG > 150 mg/dl) at the time of admission.
Exclusion Criteria:
- Pregnancy.
Contacts and Locations| Belgium | |
| Erasme University Hospital | Recruiting |
| Brussels, Belgium | |
| Contact: Dominique Durand, BS +32 255 555 44 54 ddurand@ulb.ac.be | |
| Principal Investigator: Jean-Charles Preiser, MD, PhD | |
| Sub-Investigator: Alexander Brasseur, MD | |
| Sub-Investigator: David Fagnoul, MD | |
| Principal Investigator: | Jean-Charles Preiser, MD, PhD | Erasme University Hospital |
More Information
No publications provided
| Responsible Party: | OptiScan Biomedical Corporation |
| ClinicalTrials.gov Identifier: | NCT01720381 History of Changes |
| Other Study ID Numbers: | 2001078 |
| Study First Received: | October 31, 2012 |
| Last Updated: | October 31, 2012 |
| Health Authority: | Belgium: Federal Agency for Medicinal Products and Health Products |
Keywords provided by OptiScan Biomedical Corporation:
|
monitoring blood glucose intensive care unit |
Additional relevant MeSH terms:
|
Hyperglycemia Glucose Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013